Literature DB >> 12780843

Fibrin as an inducer of fibrosis in the tunica albuginea of the rat: a new animal model of Peyronie's disease.

H H Davila1, M G Ferrini, J Rajfer, N F Gonzalez-Cadavid.   

Abstract

OBJECTIVES: To investigate the role of fibrin in inducing fibrosis in the tunica albuginea (TA) of the rat penis, to develop a new animal model for Peyronie's disease (PD).
MATERIALS AND METHODS: The TA of rats (five per group per period) were injected with either saline, fibrin, transforming growth factor-beta1 (TGF-beta1) or TGF-beta1 plus fibrin; the rats were killed at 1, 3, and 6 weeks after injection. Images were analysed quantitatively from tissue sections stained for collagen (Masson trichrome), fibrin (Verhoeff's stain) and elastin (Hart's stain), and immunostained for TGF-beta1, inducible nitric oxide synthase (iNOS), heme oxygenase 1 (HO1), alpha-smooth muscle actin (ASMA), apoptosis (TUNEL) and plasminogen activator inhibitor (PAI). Collagen fibre organization was characterized by electron microscopy. Human PD plaque tissue and normal human TA were assayed for fibrin by immunohistochemistry in nine samples.
RESULTS: At 1 week after injection of fibrin into the rat TA, only oedema was present; at 3 weeks, the oedema developed into a characteristic fibrotic PD-like plaque. The injection of TGF-beta1 into the TA also induced oedema in the TA at 1 and 3 weeks but there was very little evidence of a recognisable plaque at either time. Injection with TGF-beta1 plus fibrin resulted in oedema at 1 week but at 3 weeks there was a smaller plaque than with fibrin only. At 6 weeks the induced plaques in the fibrin-only and fibrin + TGF-beta1 groups persisted, and were comparable with those elicited at this time by TGF-beta1 alone. The control animals showed no pathology at any of the sample times. At 3 weeks the PD plaque induced by injection with fibrin alone had not only greater expression of TGF-beta1 than the TA of the animals receiving TGF-beta1 alone, but also greater levels of other markers of fibrosis, e.g. HO1 (reactive oxygen species), ASMA (presence of myofibroblasts), apoptosis, and PAI (inhibitor of fibrinolysis). iNOS, a known antifibrotic agent, was also increased. In human PD plaque tissue, fibrin was detected by immunohistochemistry in all nine specimens.
CONCLUSIONS: These results suggest that fibrin, when introduced into the TA of the rat penis, acts as a potential profibrotic protein, possibly via the local release of TGF-beta1, and induces a plaque not only histologically similar to that induced by TGF-beta1 but to that of the human condition. Because fibrin can extravasate from the blood into the human TA after an injury to the TA, and because fibrin persists in the plaque tissue, we hypothesise that fibrin may play a key role in the pathogenesis of human PD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12780843     DOI: 10.1046/j.1464-410x.2003.04224.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  25 in total

Review 1.  Therapy of erectile dysfunction: potential future treatments.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Endocrine       Date:  2004 Mar-Apr       Impact factor: 3.633

2.  PEYRONIE'S DISEASE: A REVIEW OF ETIOLOGY, DIAGNOSIS, AND MANAGEMENT.

Authors:  Aylin N Bilgutay; Alexander W Pastuszak
Journal:  Curr Sex Health Rep       Date:  2015-06-01

3.  Role of fibrin in the development of surgical adhesions.

Authors:  Jacob Rajfer
Journal:  Rev Urol       Date:  2005

Review 4.  Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy.

Authors:  Nestor F Gonzalez-Cadavid; Jacob Rajfer
Journal:  Nat Rev Urol       Date:  2010-03-09       Impact factor: 14.432

Review 5.  Nonsurgical treatment options in Peyronie's Disease: 2016 update.

Authors:  Raidh A Talib; Mohammed Abdulkareem Ibrahim; Önder Cangüven
Journal:  Turk J Urol       Date:  2016-12

Review 6.  Collagenase Clostridium histolyticum in the management of Peyronie's disease: a review of the evidence.

Authors:  Elizabeth J Traore; William Wang; Faysal A Yafi; Wayne J G Hellstrom
Journal:  Ther Adv Urol       Date:  2016-03-22

7.  Pentoxifylline treatment and penile calcifications in men with Peyronie's disease.

Authors:  James F Smith; Alan W Shindel; Yun-Ching Huang; Raul I Clavijo; Lawrence Flechner; Benjamin N Breyer; Michael L Eisenberg; Tom F Lue
Journal:  Asian J Androl       Date:  2010-11-22       Impact factor: 3.285

8.  The transcriptional signatures of cells from the human Peyronie's disease plaque and the ability of these cells to generate a plaque in a rat model suggest potential therapeutic targets.

Authors:  Robert A Gelfand; Dolores Vernet; Istvan Kovanecz; Jacob Rajfer; Nestor F Gonzalez-Cadavid
Journal:  J Sex Med       Date:  2014-12-11       Impact factor: 3.802

9.  Upregulation of mRNA expression of MCP-1 by TGF-beta1 in fibroblast cells from Peyronie's disease.

Authors:  Carolin Szardening-Kirchner; Lutz Konrad; Ekkehard W Hauck; Simone M Haag; Oliver Eickelberg; Wolfgang Weidner
Journal:  World J Urol       Date:  2008-08-14       Impact factor: 4.226

10.  The histopathological effects of intracavernosal mitomycin-C injection in a rat Peyronie's disease model.

Authors:  Engin Kaya; Yusuf Kibar; Sercan Yilmaz; Ayhan Ozcan; Burak Kopru; Turgay Ebiloglu; Hasan Cem Irkilata
Journal:  Can Urol Assoc J       Date:  2017-11       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.